CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — Q3 2022 Earnings Presentation
39 slides from CytoSorbents's earnings presentation, Nov 3, 2022
Slide 1: The Unrecognized Faces of Critical Illness
The Unrecognized Faces of Critical Illness CytoSorbents Corporation Third Quarter 2022 Earnings Conference Call November 3, 2022
Slide 2: Conference Call Participants
Conference Call Participants Moderator: Michelle Almonte CytoSorbents Corporation Phillip Chan, MD, PhD – Chief Executive Officer Vincent Capponi, MS – President and Chief Operating Officer Kathleen Bloch, MBA, CPA – Chief Financial Officer Efthymios “Makis” Deliargyris, MD, FACC, FESC, FSCAI – Chie
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward- looking statements and are subject to risks and uncertainties that could cause act
Slide 4: Operational Update
Operational Update Phillip Chan, MD, PhD Chief Executive Officer
Slide 5: Recent Operational Highlights
Recent Operational Highlights • More than 186,000 cumulative CytoSorb devices utilized as of 9/30/22, from >152,000 last year • Announced final key data from the U.S. CTC Registry on 100 critically ill COVID-19 patients with refractory respiratory failure from 5 sites, where Enhanced Lung Rest with
Slide 6: Financial Highlights
Financial Highlights Kathleen Bloch, MBA, CPA Chief Financial Officer
Slide 7: Q3 2022 Comparative Revenue Results
Q3 2022 Comparative Revenue Results Quarter Ended Quarter Ended Y-Y % Sept. 30, 2022 Sept. 30, 2021 Trend Product revenue $6.5M $8.9M (27%) Grant income $1.6M $0.9M 92% Total revenue $ 8.1M $ 9.8M (17%) • Total revenue, including product sales and grant income was $8.1M in Q3 2022 compared to $9.8M
Slide 8: Quarterly Product Sales
Quarterly Product Sales Product Sales $12.0 Core Non-COVID-19 Product Sales COVID-19 Sales $2.5 $1.7 $10.0 $2.7 $1.8 $1.7 $2.4 $9.7 $1.1 $9.0 $7.6 $0.3 $8.0 $0.0 $8.3 $1.6 $8.0 $7.8 $7.5 $6.5 $0.0 $ IN MILLONS $7.3 $7.1 $6.6 $6.5 $6.0 $5.9 $5.7 $5.5 $5.2 $5.1 $4.6 $4.0 $4.4 $4.3 $3.4 $3.0 $2.6 $2.6
Slide 9: Trailing Twelve Month Product Sales
Trailing Twelve Month Product Sales $45.0 85% $7.1 $40.0 82% 80% 77% $35.0 $6.7 $2.0 $34.8 75% $30.0 72% 74% $2.7 $ IN MILLIONS 69% $29.4 70% AXIS TITLE $25.0 $27.8 68% $20.0 $21.6 64% 65% $19.1 $15.0 60% $10.0 $11.7 55% $5.0 $7.1 $0.0 50% Q3 2016 Q3 2017 Q3 2018 Q3 2019 Q3 2020 Q3 2021 Q3 2022 * Co
Slide 10: Working Capital and Cap Table
Working Capital and Cap Table Working Capital as of 9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021 Current Assets: Cash and short-term investments* $22,552 $30,164 $43,023 $52,138 $61,043 $65,609 $68,468 Grants and accounts receivable, net 4,961 5,171 4,577 4,523 5,241 5,755
Slide 11: Extending the Cash Runway
Extending the Cash Runway • We have $24.2M in cash at September 30, 2022. We intend to further bolster our working capital by borrowing a portion of the $15M available debt facility before the end of 2022 • Cash conservation is a corporate priority, and we are continuing to focus on controlling expe
Slide 12: Commercialization Update
Commercialization Update Christian Steiner, MD Executive Vice President of Sales and Marketing Managing Director – CytoSorbents Europe GmbH
Slide 13: State of the CytoSorb community; Growth opportunities and initiatives
State of the CytoSorb community • High number of activities and customer interaction fuel the excitement • Growing support by key opinion leaders • Increasing involvement in CytoSorb projects / therapy optimization Growth opportunities and initiatives • Collaboration with Fresenius Medical Care (FMC
Slide 14: CytoSorb movement is growing
CytoSorb movement is growing CytoSorb World Users Meeting, July 1-3, Berlin, Germany • 300 KOLs from 39 countries; 26 speakers • Preview of new data sets in four different applications Italian Users Meeting (Aferetica), Sept 30/Oct 1, Milano, Italy • Focus on CytoSorb and Extracorporeal Organ Perfus
Slide 15: Excitement at several conferences
Excitement at several conferences Critical Care • COVID19 on ECMO+CytoSorb (CTC Registry) at ELSO in Boston, USA, and at ESICM in Paris, France Cardio Vascular • Infective Endocarditis at EACTS in Milano, Italy • Heart Transplantation at EACTS in Milano, Italy Liver / Kidney • Myoglobinemia at HAI i
Slide 16: Excitement at several (many) conferences
Excitement at several (many) conferences Conferences Intensivmed Regensburg | 15. – 16.07.2022 | Germany Herzanästhesie Graz | 24. – 25.06.2022 | Germany Bielefelder Infektiologie- und Intensivtag | 27.08.2022 | Germany BTS | 05.-07.09.2022 | Belfast SATS Helsinki | 07. - 09.09.2022 | Finl
Slide 17: Growth opportunities and initiatives
Growth opportunities and initiatives Global marketing agreement with FMC • Expanding the dimensions of blood purification • CytoSorb as featured solution for FMC customers • Amplification of message / Awareness / Reach / Access Stand-alone blood pump strategy • Early stage of rollout, testing differ
Slide 18: Clinical and Medical Update
Clinical and Medical Update Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI Chief Medical Officer
Slide 19: Visibility & Prioritization
Visibility & Prioritization • STAR-T is our “lead horse” to U.S. market and we are prioritizing resources to ensure speedy execution • STAR-T enrollment uptick with milestone #1 (n=40; DSMB) this month • FDA approval received to expand STAR-T to Canada, a ticagrelor “hotbed” • With better visibility
Slide 20: STAR-T now with Visibility
STAR-T now with Visibility • Increased number of study sites contributing with an uptick in enrollment • Milestone #1 (n=40) this month (PR to follow) triggering 1st DSMB review • FDA approval for Canada expansion. Potentially an important tailwind, since: • Canada is a Ticagrelor “hotbed” - ACS pro
Slide 21: STAR-T: Rationale for focus and acceleration
STAR-T: Rationale for focus and acceleration • STAR-T now executing well - we will devote our full attention and resources to fuel this momentum and speed up study completion • Canadian expansion with new Canadian ARO partner is projected to further accelerate enrollment, but to also has positive do
Slide 22: STAR-D Update
STAR-D Update • With our focus now on speeding up STAR-T completion, we will shift from a parallel to a sequential execution of the two studies • Accordingly, STAR-D activities will pause this month • There are no clinical/safety issues - This is solely a business decision • We remain fully committe
Slide 23: Cardiac Surgery: Positive New Data (EACTS)
Cardiac Surgery: Positive New Data (EACTS) Staph Aureus Antithrombotic Heart Endocarditis Removal Transplant • Better postoperative • 67% fewer transfusions • 58% lower rates of hemodynamic stabilization • 60% less chest tube postoperative vasoplegia • 63% reduction in sepsis- drainage • 62% shorter
Slide 24: Critical Care: Final CTC Registry Results (ESICM)
Critical Care: Final CTC Registry Results (ESICM) 100 patients 5 US Centers “Enhanced lung rest” ECMO + CytoSorb 74% 90-day survival - Largest and only multicenter ECMO+CytoSorb dataset - Higher survival than ECMO alone (ELSO Registry 52%) CONFIDENTIAL 24
Slide 25: Clinical/Medical Summary
Clinical/Medical Summary CLINICAL: • STAR-T accelerating plus new tailwind coming with addition of Canada • STAR-T with increased visibility - Milestone #1 this month; Milestone #2,3 next spring and summer respectively • Speedy execution of STAR-T top priority to capitalize on favorable dynamics • S
Slide 26: Business Development
Business Development Chris Cramer, MBA Vice President, Business Development
Slide 27: Emerging New Opportunities to Expand the Pool of Transplantable Organs
Emerging New Opportunities to Expand the Pool of Transplantable Organs with Ex-Vivo Perfusion and CytoSorbents Technology High Demand for More Transplants ~165,000 US and EU patients on transplant waiting list Annual Supply of Donors not Keeping Pace with Demand DBD: Donor after Brain Death DBD Dono
Slide 28: Growing Base of Promising EVP Studies for CytoSorbents' Technology
There is Growing Base of Promising EVP Studies for CytoSorbents’ Technology in Multiple Solid Organ Types Lung Kidney Liver Heart CytoSorbents Confidential 28
Slide 29: ECOS-300CY is E.U. Cleared for Ex-Vivo Organ Perfusion
ECOS-300CY is E.U. Cleared for Ex-Vivo Organ Perfusion and Ready to Support Multiple Partnering Opportunities • The ECOS-300CY sorbent cartridge has similar cytokine and inflammatory mediator removal capability to CytoSorb, but unlike CytoSorb, was specifically E.U. approved in October 2020 to remov
Slide 30: Additional Partnering Opportunities Across the Organ Transplant Ecosystem
Additional Partnering Opportunities Exist Across the Multi-Billion Dollar Organ Transplant Ecosystem Immunosuppressants Immunomodulators Organ Procurement Orgs. Ex-Vivo Perfusion Systems Intensive Care / Organ Support Surgical Equipment CytoSorbents Confidential 30
Slide 31: Global Marketing Efforts with CytoSorb Featured on FMC Website
Initiated Global Marketing Efforts with CytoSorb as a Featured Therapy on the FMC Corporate Website • FMC has begun marketing CytoSorb as a featured technology for cytokine, bilirubin, and myoglobin removal on its critical care platforms worldwide; CytoSorb can be found on FMC’s corporate website •
Slide 32: Facility and Manufacturing Update
Facility and Manufacturing Update Vincent Capponi, MS President and Chief Operating Officer
Slide 33: Quarterly Progress: R&D, New Facility
Quarterly Progress R&D New Facility 33
Slide 34: R&D
R&D • Grant programs continue to receive funding for the development of a wide range of products from removal of potassium, to anti-A and anti-B antibodies for blood transfusions. • The HemoDefend product family has received significant support from the U.S. Department of Defense with more than $17M
Slide 35: Facility/Manufacturing Update
Facility/Manufacturing Update Facility Update • ISO13485 certification for the new facility received in September • Transfer of polymer manufacturing to the new facility on track for December 2022 • Loss of product due to an equipment failure occurred in September translating into a spike in cost of
Slide 36: Facility/Manufacturing Update: Inflation
Facility/Manufacturing Update Inflation • Rising oil prices affecting raw material costs and transportations costs have pressured CytoSorb product cost • We have employed several mitigation strategies to reduce the impact of these raw material and transportation costs: • Large quantity purchases wit
Slide 37: Concluding Remarks
Concluding Remarks Phillip Chan, MD, PhD Chief Executive Officer
Slide 38: Summary
Summary • STAR-T is enrolling well and we expect to achieve the 1st milestone of STAR-T this month and are focusing our resources on driving this trial to completion, including adding Canadian centers. We have many reasons to prioritize this trial • We will temporarily pause STAR-D to focus on STAR-
Slide 39: Q&A Session
Q&A Session CytoSorbents Corporation NASDAQ: CTSO Company Contact Dr. Phillip Chan pchan@cytosorbents.com 39